Sign Up for Free!

Continue Analyzing the page and more.

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Ticker Image

US$0

US$3.6b

-2.0%

46.8%

Overview Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
Dashboard Funda..tals Deep..lue Prediction Screener Map

Scholar Rock Holding Corp Overview

Industry: Biotechnology

Sector: Healthcare

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, fibrosis, and iron-restricted anemia. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent Read More

Scholar Rock Holding Corp is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

Scholar Rock Holding Corp

Score

Recent News



Earnings Per Share

Score 3.00/5
Scholar Rock Holding Corp boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc UnitedHealth Group Incorporated IQVIA Holdings Inc
In Biotechnology industry , Vertex Pharmaceuticals Inc , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated are companies with high ratings.

Return on Equity

Score 1.20/5
Scholar Rock Holding Corp exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc UnitedHealth Group Incorporated IQVIA Holdings Inc

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

In Biotechnology industry , Vertex Pharmaceuticals Inc , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated are companies with high ratings.

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

SP500 Industry 0%

Net Margin

Score 1.26/5
Scholar Rock Holding Corp olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc UnitedHealth Group Incorporated IQVIA Holdings Inc

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

In Biotechnology industry , Vertex Pharmaceuticals Inc , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated are companies with high ratings.

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

SP500 Industry 0%

Share Buyback

In Biotechnology industry , Vertex Pharmaceuticals Inc , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated are companies with high ratings.

Leverage

Score 2.57/5
Scholar Rock Holding Corp attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc UnitedHealth Group Incorporated IQVIA Holdings Inc , also exhibit high scores.

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

In Biotechnology industry , Vertex Pharmaceuticals Inc , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated are companies with high ratings.

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

SP500 Industry 0

Financial Ratio

Yearly Quarterly

Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios

Ticker Image

Scholar Rock Holding Corp

US$0

US$3.6b

-2.0%

46.8%